Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2021/205455SARS-COV2 CORONAVIRUS RECONSTITUTED RBM AND USES THEREOF
WO 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/IL2021/050402 Applicant RAMOT AT TEL-AVIV UNIVERSITY LTD. Inventor GERSHONI, Jonathan M.
The present invention relates to vaccines and therapeutic compositions targeted at coronaviruses, specifically, the Severe Acute Respiratory Syndrome coronavirus 2 (SARS CoV2). More specifically, the invention provides reconstituted Receptor Binding Motif (RBM) of a Spike protein of the SARS CoV2, Receptor Binding domains (RBDs), and spike proteins comprising the reconstituted RBMs or τ -linkers, compositions, vaccines, therapeutic and diagnostic methods and uses thereof.
2.WO/2021/239949HUMAN RECOMBINANT MONOCLONAL ANTIBODY AGAINST SARS-COV-2 SPIKE GLYCOPROTEIN
WO 02.12.2021
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/EP2021/064352 Applicant DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E. V. (DZNE) Inventor KREYE, Jakob
The disclosure relates to a human recombinant monoclonal antibody or antibody fragment that binds the receptor binding domain (RBD) of the S1 subunit (S1) of a Spike glycoprotein of SARS-CoV-2, wherein the heavy and light chain variable amino acid sequences of the antibody (VH and VL) were isolated from convalescent COVID-19 patients. In further aspects, the disclosure relates to a nucleic acid molecule encoding an antibody or antibody fragment of the disclosure, a host cell comprising the nucleic acid molecule, and a pharmaceutical composition comprising an antibody or antibody fragment of the disclosure. The disclosure further relates to corresponding medical uses and therapeutic methods of administering an antibody or antibody fragment of the disclosure in the treatment and/or prevention of a medical condition associated with a SARS Coronavirus, in addition to diagnostic uses and methods.
3.WO/2021/216729CELLULAR VACCINE PLATFORM AND METHODS OF USE
WO 28.10.2021
Int.Class A61K 39/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
Appl.No PCT/US2021/028427 Applicant INTIMA BIOSCIENCE, INC. Inventor CHOUDHRY, Modassir
Cellular vaccine platforms, such as vaccine immune viral opsonization platforms, for eliciting host immune responses are disclosed. Also disclosed are the methods of making and using the cellular vaccine platforms in stimulating host immune responses.
4.WO/2021/211792TREATMENT OF CORONAVIRUS INFECTIONS WITH AURANOFIN
WO 21.10.2021
Int.Class A61K 31/7135
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7135Compounds containing heavy metals
Appl.No PCT/US2021/027404 Applicant GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. Inventor KUMAR, Mukesh
The present disclosure provides methods for treating viral infections, in particular treating coronavirus infections in a subject with auranofin.
5.WO/2021/229591NOVEL USE OF NON-IONIC SURFACTANT FOR THE TREATMENT OF COVID–19
WO 18.11.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/IN2020/050643 Applicant KRISHNAMACHARI, Ramu Inventor RITHVIK, K
The present invention relates to a novel use of non-ionic surfactants for the treatment of diseases caused by viruses. The present invention particularly relates to the use of non-ionic surfactants for the treatment of a disease known as COVID 19 caused by coronavirus SARS-CoV-2. The present invention further teaches the use of taste masking agents/excipients. The present invention is further believed to be related to cleansing the coronaviruses from buccal cavities, throat or within the body of a subject by not allowing the said virus to attach to any cells of mucosal layers or epithelial cells thus allowing them to pass out of the body or getting digested inside the body. For this reason the molecules or the composition used herein of the present invention is termed by the applicant as "INTERNAL SOAP".
6.WO/2021/195113COMPOSITIONS AND METHODS FOR TARGETING CORONAVIRUS USING LIPID VESICLES INCLUDING EXOSOMES
WO 30.09.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/023731 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor KALLURI, Raghu
The current disclosure provides compositions and methods for treatment and prevention of a coronavirus infection. Certain aspects are directed to lipid vesicles comprising SARS-CoV-2 spike protein or a portion or variant thereof. Further aspects include methods for treatment or prevention of a coronavirus infection comprising providing a lipid vesicle comprising a therapeutic protein, such as SARS-CoV-2 spike protein or ACE2. In some embodiments, the disclosed lipid vesicles are useful for targeted delivery of anti-viral therapeutic agents.
7.WO/2022/027088LATERAL FLOW DEVICE AND USES THEREOF
WO 10.02.2022
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/AU2021/050839 Applicant THE UNIVERSITY OF MELBOURNE Inventor GODFREY, Dale
The present disclosure provides a lateral flow assay (LFA) device for detecting neutralising antibodies against SARS-CoV-2 in a biological fluid sample, and uses thereof. The assay uses competition of the neutralising antibodies present in the sample with the ACE2-RBD on the test strip, leading to binding inhibition and decrease in signal intensity in the test region.
8.WO/2021/247925STRUCTURE-GUIDED IMMUNOTHERAPY AGAINST SARS-COV-2
WO 09.12.2021
Int.Class A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Appl.No PCT/US2021/035782 Applicant VIR BIOTECHNOLOGY, INC. Inventor CORTI, Davide
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind in certain regions of a SARS-CoV-2 S glycoprotein and can neutralize a SARS-CoV-2 infection. Also provided are immunogenic compositions that comprise a SARS-CoV-2 S glycoprotein or a portion thereof that is capable of being bound by an antibody or antigen-binding fragment.
9.WO/2022/036366REDUCTION OF COVID-19 COAGULOPATHY AND OTHER INFLAMMATION-ASSOCIATED COAGULOPATHIES BY ADMINISTRATION OF FIBROBLASTS
WO 17.02.2022
Int.Class C07K 14/50
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
50Fibroblast growth factor (FGF)
Appl.No PCT/US2021/071163 Applicant FIGENE, LLC Inventor O'HEERON, Pete
Embodiments of the disclosure include methods and compositions for treatment or reduction in risk of coagulopathy of any kind, including associated with inflammation. In specific embodiments, the coagulopathy is associated with upregulated production of tissue factor in the individual. In specific embodiments, the coagulopathy is in an individual that has SARS-CoV-2 infection or is at risk for having SARS-CoV-2 infection. In specific embodiments, the methods and compositions include fibroblasts, and/or modified fibroblasts, and/or derivatives of fibroblasts, including those fibroblasts exposed to TNF-alpha or one or more other inflammatory agents before activation of the fibroblasts.
10.WO/2022/067269ANTIBODIES AGAINST SARS-COV-2
WO 31.03.2022
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
Appl.No PCT/US2021/052481 Applicant HUMABS BIOMED SA Inventor CORTI, Davide
The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, an antibody or antigen-binding fragment is capable of binding to a SARS-CoV-2 spike protein in the N-terminal domain (NTD). Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors that comprise a polynucleotide, host cells that express an antibody or antigen-binding fragment, pharmaceutical compositions, and methods for treating or diagnosing a SARS-CoV-2 infection.